Northland Securities Predicts MiMedx Group Q1 Earnings

MiMedx Group, Inc (NASDAQ:MDXG) – Investment analysts at Northland Securities issued their Q1 2026 earnings per share estimates for shares of MiMedx Group in a research note issued to investors on Tuesday, January 20th. Northland Securities analyst C. Byrnes anticipates that the company will earn $0.02 per share for the quarter. The consensus estimate for MiMedx Group’s current full-year earnings is $0.30 per share. Northland Securities also issued estimates for MiMedx Group’s Q2 2026 earnings at $0.03 EPS, Q3 2026 earnings at $0.03 EPS, Q4 2026 earnings at $0.04 EPS and FY2026 earnings at $0.12 EPS.

MDXG has been the topic of a number of other research reports. Mizuho dropped their price objective on shares of MiMedx Group from $12.00 to $10.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 17th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of MiMedx Group in a research note on Monday, December 29th. Lake Street Capital decreased their price objective on shares of MiMedx Group from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday. Finally, Wall Street Zen upgraded MiMedx Group from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 2nd. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, MiMedx Group has an average rating of “Moderate Buy” and an average price target of $10.67.

MiMedx Group Stock Down 1.1%

NASDAQ MDXG opened at $5.33 on Wednesday. The stock has a market cap of $789.37 million, a PE ratio of 19.74 and a beta of 1.57. MiMedx Group has a fifty-two week low of $5.13 and a fifty-two week high of $9.30. The business has a 50 day moving average price of $6.66 and a two-hundred day moving average price of $6.89. The company has a quick ratio of 3.95, a current ratio of 4.41 and a debt-to-equity ratio of 0.07.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings data on Wednesday, October 29th. The company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.07 by $0.08. MiMedx Group had a return on equity of 27.19% and a net margin of 10.38%.The company had revenue of $113.73 million for the quarter, compared to analysts’ expectations of $94.74 million.

Insider Activity

In other news, insider Kimberly Maersk-Moller sold 58,300 shares of the stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $7.42, for a total transaction of $432,586.00. Following the transaction, the insider owned 236,982 shares of the company’s stock, valued at approximately $1,758,406.44. This trade represents a 19.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 1.70% of the company’s stock.

Institutional Trading of MiMedx Group

Hedge funds and other institutional investors have recently bought and sold shares of the company. CWM LLC increased its holdings in shares of MiMedx Group by 63.8% in the 2nd quarter. CWM LLC now owns 4,857 shares of the company’s stock worth $30,000 after acquiring an additional 1,892 shares during the period. PNC Financial Services Group Inc. grew its position in MiMedx Group by 1,808.4% in the 2nd quarter. PNC Financial Services Group Inc. now owns 7,500 shares of the company’s stock worth $46,000 after purchasing an additional 7,107 shares during the last quarter. State of Alaska Department of Revenue acquired a new stake in shares of MiMedx Group in the third quarter valued at approximately $54,000. Wealth Enhancement Advisory Services LLC bought a new stake in shares of MiMedx Group during the third quarter valued at approximately $84,000. Finally, Allianz Asset Management GmbH acquired a new position in shares of MiMedx Group during the third quarter worth approximately $82,000. 79.15% of the stock is owned by institutional investors.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.